Autolus reports early progress with cancer drugs
Syncona Limited NPV
128.40p
16:40 26/04/24
Autolus Therapeutics reported progress in clinical trials for one of its cancer treatments and said it has begun dosing patients in another trial.
Autolus Therapeutics Plc
$4.11
07:09 26/04/24
Equity Investment Instruments
11,766.90
16:59 26/04/24
FTSE 250
19,824.16
16:59 26/04/24
FTSE 350
4,470.09
16:59 26/04/24
FTSE All-Share
4,423.59
16:55 26/04/24
Syncona, which is listed on the Nasdaq in New York and where FTSE 250-listed Syncona is a 33.8% shareholder, its Phase I/II Amelia clinical trial of AUTO3 in patients with relapsed/refractory pediatric acute lymphoblastic leukemia had so far shown a "manageable" safety profile, "with the potential to overcome target-negative relapse", which has proved a limitation of current treatments.
Early results of the ongoing Phase 1/2 Alexander trial of AUTO3 in patients with relapsed/refractory diffuse large B cell lymphoma, also indicate a manageable safety profile.
Meanwhile, a trial of its AUTO4 developmental therapy for the treatment of relapsed or refractory TRBC1-positive peripheral T cell lymphoma has just begun dosing patients.
Furthermore, Autolus presented data over the weekend on the preclinical sister program, AUTO5, targeting TRBC2-positive lymphoma. Autolus' T cell program comprises a companion diagnostic to determine whether the PTCL is TRBC1- or TRBC2-positive and two novel CAR T cell product candidates AUTO4 and AUTO5. The company suggested that employing a structural biology approach and molecular modelling techniques, a binder was generated that could bind TRBC2 without binding to TRBC1, which could selectively eliminated TRBC2-positive cells.